





# LIVE WEBINAR

## Prader-Willi syndrome: challenges and best practice solutions for each life stage



Friday, 18 June 2021  
from 10:00 to 11:00 CEST  
from 17:00 to 18:00 KST





## OVERVIEW

Prader-Willi syndrome (PWS) is a multisystemic complex genetic disorder affecting thousands of children worldwide. Clinical manifestations and the needs of the family change with the age of the child, starting from the neonatal period. Infants with PWS have hypotonia, feed poorly and fail to thrive. During adulthood, morbidity and mortality secondary to severe obesity are increased. During the period in between, other features such as short stature, food seeking with excessive weight gain, developmental delay, cognitive disability, behavioral problems and hypothalamic dysfunction become evident. Multiple endocrine abnormalities (including growth hormone and thyroid-stimulating hormone deficiencies, hypogonadism and central adrenal insufficiency) complicates management of the clinical scenario. A multidisciplinary approach and the continuation of care throughout the child's life are essential to support patients and families as they face these issues. This live webinar is intended for healthcare professionals involved in the care of children with PWS. The main aim is to provide the most up-to-date knowledge and clinical research on PWS, to help ensure all care of patients with PWS is of the highest standard and using the latest guidelines and best practice at each stage of the patient's life. It will provide a chance for participants to consider and refresh their understanding of PWS, and a forum for the discussion of the ongoing, unresolved issues with this condition.

## LEARNING OBJECTIVES

After attending the live webinar participants will learn:

- How to recognize PWS in the first year of life
- What are the most important actions for the clinician to take after diagnosing a baby with PWS
- The role of rhGH from infancy until adolescence
- The benefits of continuing rhGH into adulthood
- How to manage patient follow-up throughout adulthood
- The use of technology to support patients with PWS

## TARGET AUDIENCE

This activity is designed for all healthcare providers involved in the care of patients with PWS during child- and adulthood. The content will be particularly relevant to pediatricians, endocrinologists, general practitioners and nurses involved in the care of those with PWS.

## LANGUAGE

The official language of this live educational webinar is English.

Simultaneous translation into Spanish and Korean will be provided.

## REGISTRATION AND SURVEY

To access the live webinar, please register by clicking on the below link:

**<https://www.elearning.scientificseminars.com/the-2021-digital-learning-journey-on-growth-disorders/live-webinar/>**

and complete a very short survey covering your current knowledge of the subject matter prior to attending the webinar.

## CONTINUING MEDICAL EDUCATION

**The Prader-Willi syndrome: challenges and best practice solutions for each life stage, Rome, Italy, 18/06/2021-18/06/2021** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **1 European CME credit (ECMEC®)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.




## CME PROVIDER

### Scientific Seminars International Foundation

Senior CME Manager: Flaminia Masprone  
T +39 380 1504116 - F +39 06 4827169  
[info@scientificseminars.com](mailto:info@scientificseminars.com)

Scientific Program by:  
Claudio Giacomozzi, MD  
Paediatric Endocrinology Unit  
Carlo Poma Hospital  
ASST-Mantova



## FACULTY

### **Malcolm Donaldson**

Honorary Senior Research Fellow  
University of Glasgow  
Child Health Section  
Glasgow, United Kingdom

### **Martin Savage**

Emeritus Professor of Pediatric  
Endocrinology  
The William Harvey Research Institute  
London, United Kingdom

### **Han-Wook Yoo**


Emeritus Professor of Pediatrics,  
Medical Genetics & Genomics,  
Asan Medical Center Children's  
Hospital  
University of Ulsan College of  
Medicine  
Seoul, Korea

**FRIDAY, 18 JUNE 2021**  
from 10:00 to 11:00 CEST

|       |           |                                                                                                                                                            |
|-------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.00 |           | <b>Welcome and introduction</b><br>M. Savage (UK)                                                                                                          |
| 10.05 | <b>L1</b> | <b>The Prader-Will syndrome – recognition during infancy, management in childhood and adolescence, and the role of growth hormone</b><br>M. Donaldson (UK) |
| 10.30 | <b>L2</b> | <b>Transition to adult care: could there be benefits of continuation of rhGH treatment into adult life?</b><br>Han-Wook Yoo (Korea)                        |
| 10.55 | <b>P</b>  | <b>Panel discussion</b>                                                                                                                                    |
| 11.05 |           | <b>Closing remarks</b><br>M. Savage (UK)                                                                                                                   |
| 11.10 |           | <b>End of the live webinar</b>                                                                                                                             |

**LEGEND**

**L:** Lecture; **P:** Panel discussion



## FACULTY DISCLOSURES

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

|                          |                                             |
|--------------------------|---------------------------------------------|
| <b>Malcolm Donaldson</b> | Declared no potential conflict of interest. |
| <b>Martin Savage</b>     | Declared no potential conflict of interest. |
| <b>Han-Wook Yoo</b>      | Declared no potential conflict of interest  |

## CHAIRMAN



### Martin Savage

Martin Savage is Professor emeritus of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, (UK), following 15 years as head of the Paediatric Endocrine Unit at Barts and the London School of Medicine. He is a clinician with clinical and research interests in growth disorders - specifically those involving abnormalities in the growth hormone-IGF-1 axis. His main research field has been the phenotype- genotype relationships of GH-IGF-1 axis defects, notably growth hormone resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other clinical interests are Cushing's syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. Professor Savage has lectured in 59 countries world-wide and has published more than 450 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. He continues to lecture nationally and internationally.

## L1

### **The Prader-Willi syndrome – recognition during infancy, management in childhood and adolescence, and the role of growth hormone**

Malcolm Donaldson (UK)



#### **LEARNING OBJECTIVES**

- Learn the genetic basis and prevalence of Prader-Willi syndrome (PWS)
- Understand the presenting features of PWS during the fetal/perinatal and infantile phases, and thus make the diagnosis early
- Appreciate the natural history of PWS from birth to adulthood and hence the scope of the problem facing patients and their families
- Understand the key management aspects of PWS from infancy to adult transfer, including dietary control and physical exercise
- Learn how growth hormone therapy can be used safely and effectively in PWS

#### **Malcolm Donaldson**

Malcolm Donaldson is an Honorary Senior Research Fellow with Glasgow University, and divides his time between writing, research, and teaching. Dr Donaldson is particularly involved with international teaching, has been on the faculties of the European Society for Paediatric Endocrinology (ESPE) Winter School and Maghreb Schools, and is currently on the faculty of the ESPE Caucasus and Central Asian School. Malcolm Donaldson is interested in collaborative research. He is a member of the Steering Committee of the ESPE Turner syndrome Working Group, which advocates international studies into different methods of pubertal induction. He is hoping to encourage a randomised cross-over study of oral sex hormone replacement in Prader Willi syndrome (PWS) in the UK, aimed at resolving concerns over the possible effects of such treatment on behaviour. During his appointment as Senior Lecturer in Child Health in Glasgow, Dr Donaldson developed endocrine outreach clinics, including specialist clinics for patients with Turner syndrome. In 1991, he helped create a multidisciplinary clinic for patients with PWS, with input from Child and Adolescent Psychiatrists, Dietitians, a Specialist Endocrine Nurse and Auxologist. Until Dr Donaldson's retirement in 2012, resources for adult PWS care in Scotland were few and so the PWS clinic saw child, adolescent and adult patients.

## L2

### **Transition to adult care: could there be benefits of continuation of rhGH treatment into adult life?**

Han-Wook Yoo (Korea)

#### **LEARNING OBJECTIVES:**


- Increase awareness of the clinical and endocrinological issues during the transition period for patients with Prader Willi syndrome (PWS)
- Discuss the benefits and potential adverse effects of continuing growth hormone therapy (GH) into adult life in patients with PWS
- Learn how to manage patient follow-up throughout adult life



#### **Han-Wook Yoo**

Han-Wook Yoo is Emeritus Professor in the Department of Pediatrics and Medical Genetics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, South Korea. His medical and scientific training included three years at the Mount Sinai Medical Center Department of Pediatrics, in New York (USA), where he became certified as a clinical molecular geneticist by the American Board of Medical Genetics.

Professor Yoo's main research interests are focused on the characterization of molecular and functional defects of endocrine genetic disorders, and he has published more than 250 peer-reviewed articles in this field. He has received several awards for his research and is an active member of many international academic societies for endocrinology and medical genetics.



All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation. This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt Germany.



Scientific Seminars International Foundation  
Via di Porta Pinciana, 6 - 00187 Roma  
[www.scientificseminars.com](http://www.scientificseminars.com)

Copyright © Scientific Seminars International Foundation, 2021. All rights reserved.